A long-acting intramuscular injectable or depot form of paliperidone was listed on the Pharmaceutical Benefits Scheme (PBS) as Authority required (streamlined) on 1 December 2011*.1,2 It is an alternative to existing long-acting antipsychotics for people
with schizophrenia. A maintenance dose is given once a month.3 Paliperidone is the main active metabolite of risperidone2: refer to the product information for information about switching people from oral paliperidone, or oral or injectable
risperidone, to injectable paliperidone.3
*Paliperidone tablets have been PBS listed (Authority required [streamlined]) for schizophrenia since 1 April 2008.
Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer. This website uses cookies. Read our privacy policy.
